A 35-year-old patient taking both Lunesta (eszopiclone) and Sonata (zaleplon) – should they discontinue one of the hypnotics?

Discontinue One Hypnotic Immediately—Concurrent Use of Lunesta and Sonata Is Not Evidence-Based and Increases Serious Harm

A 35-year-old taking both eszopiclone (Lunesta) and zaleplon (Sonata) should discontinue one agent immediately; combining two sedative-hypnotics without clear indication markedly raises the risk of complex sleep behaviors, respiratory depression, and other serious adverse events. 1, 2

---

Why Dual Hypnotic Therapy Is Inappropriate

• Both eszopiclone and zaleplon are nonbenzodiazepine GABA-A receptor agonists (Z-drugs) that act on overlapping receptor subtypes, producing additive CNS depression without complementary mechanisms. 3
• The FDA drug labels for both Lunesta and Sonata explicitly warn that combining sedative-hypnotics produces additive CNS-depressant effects, increasing the risk of complex sleep behaviors (sleep-driving, sleep-eating, amnesia) and serious injuries including death. 1, 2
• A 2020 FDA safety analysis identified 66 cases of complex sleep behaviors resulting in serious injuries or death with Z-drugs, including carbon monoxide poisoning, drowning, falls, hypothermia, motor vehicle collisions, and completed suicide; 22 of these cases had a prior episode of complex sleep behavior before the fatal or near-fatal event. 4
• The FDA has mandated a Boxed Warning and Contraindication for patients who have experienced a prior complex sleep behavior with a Z-drug, underscoring that even monotherapy carries substantial risk—dual therapy amplifies this danger. 4

---

Which Agent to Discontinue: Evidence-Based Decision Algorithm

Step 1: Identify the Primary Sleep Complaint

• If the patient has isolated sleep-onset insomnia (difficulty falling asleep but maintains sleep once asleep):

  • Discontinue eszopiclone and continue zaleplon 10 mg. 5
  • Zaleplon has an ultra-short half-life (~1 hour) and is specifically indicated for sleep-onset insomnia with minimal next-day residual effects. 6
  • The American Academy of Sleep Medicine recommends zaleplon for sleep-onset difficulty based on strong RCT evidence. 5

• If the patient has sleep-maintenance insomnia (frequent awakenings or early-morning awakening):

  • Discontinue zaleplon and continue eszopiclone 2–3 mg. 5
  • Eszopiclone demonstrates the most robust long-term efficacy among hypnotics for both sleep onset and maintenance, with RCT data supporting use beyond 4 weeks. 5, 7
  • The 3 mg dose is more effective for sleep maintenance than the 2 mg dose. 7

• If the patient has both sleep-onset and sleep-maintenance problems:

  • Discontinue zaleplon and continue eszopiclone 2–3 mg, as eszopiclone is the only Z-drug with evidence for treating both components of insomnia. 5, 7

Step 2: Taper the Discontinued Agent Appropriately

• Eszopiclone discontinuation:

  • Taper by reducing the dose by 50% every 3–7 days (e.g., 3 mg → 1.5 mg → discontinue) to minimize rebound insomnia and withdrawal symptoms. 8, 9
  • Delay initiation of the next therapy (if switching) by 1–2 days after the final eszopiclone dose, especially if the patient was on supratherapeutic doses. 9

• Zaleplon discontinuation:

  • No taper is required for zaleplon due to its ultra-short half-life and lack of evidence for withdrawal symptoms or rebound insomnia. 9, 6
  • Zaleplon can be stopped abruptly without a washout period before continuing eszopiclone. 9

---

Additional Safety Measures and Monitoring

• Counsel the patient that both agents carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, amnesia) and that these risks are dose-dependent and amplified by alcohol or other CNS depressants. 1, 2, 4
• Strongly advise against alcohol use with any remaining hypnotic, as the FDA labels for both drugs explicitly state they should not be taken with alcohol. 1, 2
• Reassess after 7–10 days: If insomnia does not remit, this may indicate an underlying psychiatric or medical disorder (e.g., depression, sleep apnea, restless legs syndrome) that requires evaluation rather than escalation of hypnotic therapy. 1, 2
• Consider cognitive-behavioral therapy for insomnia (CBT-I) as the first-line treatment; the 2019 VA/DoD guideline found CBT-I superior to pharmacotherapy in long-term outcomes with fewer adverse effects. 10

---

Agents to Avoid in This Patient

• Do not add or switch to trazodone: The American Academy of Sleep Medicine explicitly recommends against trazodone for insomnia due to insufficient efficacy (only 1.38% improvement in sleep efficiency vs. placebo, 95% CI −2.87 to 5.63). 5
• Do not add or switch to benzodiazepines (e.g., temazepam, triazolam): The 2019 VA/DoD guideline advises against benzodiazepines due to high risks of dependency, falls, cognitive impairment, and respiratory depression, especially in patients already on a Z-drug. 10
• Do not add or switch to over-the-counter antihistamines (e.g., diphenhydramine): The American Academy of Sleep Medicine explicitly discourages these agents due to anticholinergic adverse effects and lack of efficacy. 5

---

Common Pitfalls to Avoid

• Continuing dual hypnotic therapy "because the patient has been stable": Stability does not negate the cumulative risk of serious injury or death from complex sleep behaviors, which can occur unpredictably even after prolonged use. 4
• Assuming zaleplon is "safer" because of its short half-life: While zaleplon has fewer next-day residual effects, it still carries the same FDA Boxed Warning for complex sleep behaviors as eszopiclone and zolpidem. 4
• Failing to address the underlying cause of insomnia: Chronic insomnia lasting beyond 7–10 days of treatment often reflects an unrecognized psychiatric (e.g., depression, anxiety) or medical disorder (e.g., obstructive sleep apnea, chronic pain) that requires targeted intervention rather than indefinite hypnotic use. 1, 2